Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999–2018 study
Inclisiran has the potential to substantially reduce the prevalence of hypercholesterolemia and prevent nearly 200,000 CVD events in eligible US adults.
Authors
- Jiawen Wu (ORCID: https://orcid.org/0000-0002-6286-5937)
- Jun Young Han (ORCID: https://orcid.org/0000-0003-0798-704X)
- Haonan Li (ORCID: https://orcid.org/0009-0007-7727-3532)
- Yi Zhang (ORCID: https://orcid.org/0000-0002-2285-0087)
- Yawei Xu (ORCID: https://orcid.org/0000-0002-1172-4165)
- Song Zhao (ORCID: https://orcid.org/0000-0002-1284-883X)
- Shengfeng Shi
Institutions
- Tongji University (CN)
- Nantong University (CN)
- Second People's Hospital of NanTong (CN)
- Shanghai Tenth People's Hospital (CN)
- Guizhou Provincial People's Hospital (CN)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12944-024-02294-8
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- National Natural Science Foundation of China